Physician profile
Sean O'Leary Mcmenomey
NPI 1578578076
$27,139.34
in general payments reported to CMS, 2019-2025
9 companies · $9,479 in 2025
The $9,479 reported for 2025 was more than what 89% of Otology & Neurotology providers received nationally (typical 2025 total: $411).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $3,891 · 2021: $2,333 · 2022: $688 · 2023: $1,108 · 2024: $8,824 · 2025: $9,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $9,672 · Consulting Fee: $8,000 · Food and Beverage: $1,739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $9,672.15 |
| Consulting Fee | $8,000.00 |
| Food and Beverage | $1,738.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cochlear Americas | $22,286.54 | 2019-2025 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Advanced Bionics, LLC | $3,835.00 | 2020 | |
| Med-El Corporation | $627.32 | 2023 | Mi1250 Synchrony 2 Flexsoft, Adhear Professional Kit, Bci 602 Kit |
| Grace Medical, INC. | $152.48 | 2019 | |
| Stryker Corporation | $75.36 | 2025 | Duramatrix, Adherus Autospray Dural Sealant, Hydroset |
| Cochlear Ag | $56.18 | 2020 | |
| Novartis Pharmaceuticals Corporation | $38.41 | 2019 | |
| Integra Lifesciences Corporation | $36.21 | 2025 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
| Axogen | $31.84 | 2024 | Axoguard Nerve Cap, Axoguard Nerve Protector, Axoguard Ha+ Nerve Protector |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Mcmenomey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.